RMRavi Mandla

Ravi Mandla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ravi Mandla has a total of 403 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systematic comparison of phenome-wide admixture mapping and genome-wide association at biobank-scale

    by Sinead Cullina, Ruhollah Shemirani, Zhuozheng Shi, Ravi Mandla, Bogdan Pasaniuc, Samira Asgari, Eimear E. Kenny

    Opportunities remain to leverage population structure in large scale genomic studies for additional insight. Admixture mapping (AM) identifies loci where disease risk differs by ancestral background, offering a complementary strategy to genome-wide association studies (GWAS) in admixed populations. We performed a systematic comparison of AM and GWAS across over 800 clinical phenotypes in Hispanic/Latino (HL) and African American (AA) participants from the BioMe biobank. We developed a well-calibrated AM pipeline tailored to the local ancestry structure of HL (N = 14,876) and AA (N = 8,819). While GWAS identified a greater number of significant associations, AM revealed 77 signals, including 48 not detected by GWAS. AM-tagged variants had higher minor allele frequency and population differentiation (Fst), while GWAS demonstrated higher odds ratios, underscoring the distinct genetic architecture identified by each method. This study emphasizes the importance of applying both GWAS and AM approaches to uncover previously unreported loci in admixed populations.

  • All of Us diversity and scale yield context-dependent improvements in polygenic prediction

    by Kristin Tsuo, Zhuozheng Shi, Tian Ge, Ravi Mandla, Kangcheng Hou, Yi Ding, Bogdan Pasaniuc, Ying Wang, Alicia R. Martin


  • Open Access

    Novel type 1 diabetes polygenic scores improve identification of type 1 diabetes in diverse populations

    by Stella Nam, Raymond J. Kreienkamp, Jiang Li, Ravi Mandla, Huy Tran, Katherine Taylor, Maheak Vora, Alicia Huerta-Chagoya, Jun Wei, Ashley J. Mulford, et al.

    Most polygenic scores (PS) for type 1 diabetes were developed using European (EUR) ancestry datasets, limiting performance in non-European (non-EUR) populations. We evaluated novel type 1 diabetes PS across diverse populations to assess whether newer models improve prediction in underrepresented populations. Seven type 1 diabetes PS (T1D GRS2, T1D GRS2′, T1D GRS HLA , T1GRS, TA-PS, TA-PS (S), T1D MAPS) were evaluated in All of Us and Mass General Brigham Biobank. Predictive performance was assessed using the area under the receiver operating characteristic curve (AUC). T1D GRS2 and T1D MAPS showed the highest AUC in All of Us, while other scores demonstrated comparatively lower performance. These highest-performing scores were then evaluated in a meta-analysis across three additional biobanks (Genomic Health Initiative at Endeavor Health, Penn Medicine BioBank, Geisinger MyCode). Among 2,782 individuals with type 1 diabetes and 546,577 controls, T1D MAPS showed comparable performance to T1D GRS2 in EUR populations but significantly improved discrimination in non-EUR populations (meta-analysis ΔAUC=0.049, p =1.7×10 −7 ). Overall, T1D MAPS improves prediction in non-EUR populations, highlighting the importance of multi-ancestry approaches for equitable genetic risk prediction. These findings could inform precision medicine in diverse populations.

  • Open Access

    Large-scale admixture mapping in the All of Us Research Program improves the characterization of cross-population phenotypic differences

    by Ravi Mandla, Zhuozheng Shi, Kangcheng Hou, Ying Wang, Georgia Mies, Alan J. Aw, Sinead Cullina, Alan Aw, Eimear Kenny, Iain Mathieson, et al.

    Admixed individuals have been understudied in medical research largely due to their complex genetic ancestries. However, the consideration of admixture can identify ancestry-enriched genetic associations, delineating genetic underpinnings of cross-population phenotypic variation. Here, we performed admixture mapping in individuals with inferred admixture from African and European populations (N = 48,921). Across 22 traits, we identified 71 ancestry-trait associations, including loci where ancestral haplotypes explained phenotypic variation yet were missed by single-variant association testing due to their stricter multiple testing burden. One such locus where inferred local AFR ancestries are associated with increased hemoglobin A1c (HbA1c) was 12q14.3, highlighting its potential role in explaining differences between populations. Together, our results expand upon the phenotypic differences between populations and characterize loci where genetic ancestries play a critical role in the architecture of disease.


  • Open Access

    A unified framework for local-ancestry-aware genetic association analysis across biobanks

    by Linfeng Hu, Taotao Tan, Kai Yuan, Ying Wang, Bram L. Gorissen, Yi-Sian Lin, Pragati Kore, Wenhan Lu, Ravi Mandla, Zhuozheng Shi, et al.

    Biobanks increasingly include individuals with admixed genomes, yet conventional genome-wide association study frameworks either exclude participants who cannot be confidently assigned to a discrete ancestry group or ignore ancestry-specific effects. We present FELIX, a scalable framework for local-ancestry-aware genetic analysis that retains all participants without requiring discrete ancestry assignment. FELIX combines a compact ancestry-resolved genotype representation (FELIXla) with an adaptive association test that jointly evaluates shared-effect and ancestry-specific models at each variant (FELIXassoc). Simulations demonstrated well-calibrated inference under case-control imbalance and power that adapted to the locus-optimal model. Across 24 phenotypes in 240,038 All of Us participants, FELIX analyzed the 12.1% of individuals excluded by global-ancestry clustering and identified 15.4% more genome-wide significant loci than global-ancestry meta-analysis. Additional discoveries arose from recovering ancestry-specific haplotypes carried by admixed participants and from detecting ancestry-dependent marginal effects. Full-cohort effect estimates also improved polygenic score prediction across ancestries and traits.

  • Integrative analyses elucidate transcriptional regulatory functions of risk alleles for metabolic liver disease

    by Biying Zhu, Na He, Yang Xiao, Bin Chen, Chen Li, Ravi Mandla, Yifan Liu, Jiayu Zhang, Xiao Chang, Fulong Yu, et al.

    Genome-wide association studies have identified >100 loci associated with metabolic dysfunction-associated steatotic liver disease (MASLD), yet the mechanisms by which noncoding variants alter disease risk remain unclear. Here we map chromatin accessibility in human MASLD liver nuclei, revealing enrichment of risk variants within cell-type-specific regulatory elements bound by lineage-determining transcription factors. Using a massively parallel reporter assay, we identified hundreds of differential activity variants (DAVs) that act in a cell-type-dependent and stimulus-dependent manner and perturb transcriptional regulatory networks linked to liver pathology. Integration of liver expression quantitative trait loci, chromatin looping and single-cell CRISPR interference screening assigns target genes to these DAVs. Importantly, DAVs at numerous loci, including SLC22A3 and key triglyceride metabolism regulators (APOA5, ANGPTL3 and LPL), modulate gene expression, lipid metabolism and hepatic stellate cell activation. Moreover, these DAVs allow improved prediction of MASLD risk. These results define a regulatory framework linking noncoding genetic variation to MASLD pathogenesis.


  • Open Access

    CalPred yields calibrated intervals for polygenic risk prediction

    by Zhuozheng Shi, Zixuan (Eleanor) Zhang, Ravi Mandla, Kangcheng Hou, Bogdan Pasaniuc

    Polygenic scores (PGS) have emerged as a useful biomarker for stratification of high-risk individuals in genomic medicine, with prediction intervals arising as a principled approach to incorporate statistical uncertainty in their individual-level predictions. In contrast to recent reports by Xu et al 7 , we show that CalPred 6 provides well-calibrated prediction intervals that contain the trait phenotypes at targeted confidence levels. CalPred maintains calibration when PGS performance varies across contextual factors (e.g., ancestry, age, sex, or socio-economic factors) whereas PredInterval 7 – a recently introduced method that focuses on marginal calibration across all individuals – exhibits miscalibration.


  • Open Access

    Implementation of the genome-informed risk assessment (GIRA) may lead to large disruptions to the health system

    by Sandra Lapinska, Xinzhe Li, Ravi Mandla, Zhuozheng Shi, Veronica Tozzo, Alexander Flynn-Carroll, Marylyn D Ritchie, Daniel J Rader, Bogdan Pasaniuc

    The Genome Informed Risk Assessment (GIRA) report from eMERGE has become a standard approach to implement genomic precision medicine at scale. Here, we assess GIRA's utility and impact in a health care system independent of eMERGE, focusing on 9 adult conditions using the Penn Medicine Biobank (PMBB, n=48,279). We find a large number of patients - 50.1% (n=24,185) - were deemed by GIRA as high-risk for at least one of the 9 conditions with 30.4% (n=14,676) due to polygenic and/or monogenic risk. Stratifying by ancestry revealed significant differences in high-risk proportions, with higher rates in African/African American (AFR) (56.6% vs. 50.1%, p=7.43x10-36) and lower rates in East (42.0%) and South Asian (40.0%). Increased high-risk rates were observed in the lowest quartile of social deprivation index, highlighting the influence of environmental factors and access to care on GIRA's utility. GIRA was a good predictor of prevalent cases (in-line with the eMERGE GIRA reported results); incident case prediction was substantially attenuated for 5 of the 9 conditions (e.g., OR of 2.36 vs. HR of 1.31 for atrial fibrillation (AFIB)). We find demographic compositions of high-risk patients differed from the incident cases for some of the conditions; for example, high-risk for AFIB individuals where enriched for European ancestries in contrast with incident AFIB cases that were enriched for AFR ancestries. Overall, our results show the accuracy of GIRA as a biomarker to stratify high-risk patients for precision medicine and highlight implementation challenges in its impact on the health system if implemented at scale.

  • Open Access

    Statistical uncertainty explains the poor agreement in polygenic scoring for type 2 diabetes

    by Ravi Mandla, Xinzhe Li, Zhuozheng Shi, Sarah A. Abramowitz, Sandra Lapinska, Penn Medicine Biobank, Michael G. Levin, Scott M. Damrauer, Bogdan Pasaniuc

    Polygenic scores (PGS) have emerged as an important tool for genetic risk prediction in medicine to identify individuals at high-risk for disease. A major limitation in their implementation is the apparent disagreement among scores for the same individual decreasing their interpretability and utility in clinical settings. Here we show that the poor agreement across PGSes for type 2 diabetes (T2D) is fully explained by statistical uncertainty in PGS-based prediction; individual-level uncertainty estimates from a single PGS explain the variability across existing PGSes. We provide an approach for the selection of high-risk individuals that incorporates measures of uncertainty and show that individuals with high confidence based on their PGS uncertainty have higher risk agreement across existing PGS and are more likely to develop T2D than high-risk individuals based on only point estimates of PGS. Together, these findings shed light on the factors underlying a roadblock in PGS implementation and underscore the need to incorporate uncertainty in PGS-based predictions.

  • Open Access

    Genome-wide analysis implicates inner ear development in Ménière’s disease

    by Zhuozheng Shi, Ravi Mandla, Jingjing Li, Xinzhe Li, Zixuan (Eleanor) Zhang, Sixing Chen, Sandra Lapinska, Alexander O. Flynn-Carroll, Bogdan Pasaniuc, Douglas J. Epstein, et al.

    Ménière’s disease (MD) is a chronic inner ear disorder characterized by recurrent vertigo, fluctuating sensorineural hearing loss, and tinnitus. Despite these distinctive symptoms, its etiology remains poorly understood. We performed a genome-wide meta-analysis of 8,969 cases and 1,962,542 controls across five large biobanks, identifying five independent genome-wide significant loci and estimating an observed-scale SNP heritability of 7% (SE 0.8%), consistent with a modest but significant genetic contribution to MD risk. Fine-mapping and integrative functional analyses implicate two convergent biological processes – developmental regulation of the inner ear, involving EYA4, EYA1 , and LMO4 – and retinoic acid metabolism, with loci near CYP26A1/C1 and ALDH1A2 suggesting disrupted RA signaling in sensory and fluid-pressure homeostasis. These developmental regulator genes are robustly expressed in fetal and adult human inner ear cell types, supporting a model in which altered developmental programs predispose to adult vestibular and auditory dysfunction. Phenome-wide and genetic correlation analyses further reveal shared genetic architecture between MD and related traits, including vertigo, tinnitus, hearing loss, migraine, and sleep apnea, situating MD within a broader spectrum of sensory and neurological disorders. Collectively, these findings establish a genetic framework for Ménière’s disease risk and implicate developmental regulators and retinoic acid signaling as key contributing pathways.